viewInstem PLC

Instem says all three businesses performed well in first half

Instem develops and sells software that aids data collection and the regulatory submission process for drugmakers

Instem PLC -

Instem PLC (LON:INS) enjoyed a solid first half as it cited the financial restructuring of recent years and the “increasing efficacy” of the company’s technology and services for its success.

All three parts of the business – data collection, informatics and regulatory solutions – performed well in the six months ended June 30, investors were told.

Total revenues grew by 11% to £11.7mln, while new software as a service income more than doubled to £1.1mln. Recurring sales, meanwhile, were £7mln.

Underlying earnings (EBITDA) advanced £300,000 to £1.7mln, while basic EPS were 2p, up from 0.3p a year earlier.


Importantly for a growing business, Instem saw a net operating cash inflow of £3.2mln, double the figure at the same point last year. Its cash balance was £6mln as at the period-end.

The company said it expects to recognise £1mln of a £1.7mln contract with Provantis in the second half.

Chief executive Phil Reason said the market backdrop for its products was positive, “with the pharmaceutical industry increasing investment in the types of software and services Instem provides to match the expanding drug pipeline and to satisfy increasing regulatory requirements”.

Technology helps customers get products to market faster 

Instem develops and sells software that aids data collection and the regulatory submission process for drugmakers.

In short, its tech helps its customers to bring their products to market faster.

The AIM firm owns more than a dozen software applications, including its flagship SEND technology. SEND stands for Standard for the Exchange of Nonclinical Data and is a protocol set up by the US Food and Drug Administration. It ensures that companies present data in a consistent format.

Among Instem’s other top products is Samarind – a software-as-a-service (SaaS) platform that enables companies to register and track their regulated products worldwide by maintaining a single integrated database, which is then used to update drugs watchdogs as products change over time.

Looking ahead, CEO Reason told the market: “Strong order intake and pipeline growth during the period enabled accelerated investment in personnel to ensure we execute on these opportunities.”

Quick facts: Instem PLC

Price: 515 GBX

Market: AIM
Market Cap: £105.48 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Instem PLC named herein, including the promotion by the Company of Instem PLC in any Content on the Site, the Company receives from said issuer...


Instem PLC has 'significant capital' to accelerate acquisition strategy...

Instem PLC's (LON:INS) Phil Reason tells Proactive London's Andrew Scott he's pleased with its first-half trading. He says the number's were in line with forecasts and momentum has continued into the second half. Revenues for the six months ended June 30, 2020, were up 20%, or 12% on a...

on 22/7/20

2 min read